Rhumbline Advisers Entrada Therapeutics, Inc. Call Options Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TRDA
# of Institutions
106Shares Held
28.6MCall Options Held
15.7KPut Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$25.1 Million0.33% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$22.6 Million67.92% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.31MShares$22.2 Million19.43% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.57MShares$13.2 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$8.74 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $162M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...